The risks associated with platelet refractoriness may affect decision-making when considering autologous stem cell transplantation in patients with anti-human leucocyte antigen (HLA) antibodies. We describe a case of lifethreatening haemorrhage in a young woman who underwent high-dose chemotherapy and peripheral blood stem cell transplant (PBSCT) complicated by anti-HLA antibodies. rVIIa was administered when matched platelets and other blood product therapy had failed to stem bleeding. Haemostasis was rapidly achieved with evidence of marked thrombin generation despite on-going severe thrombocytopenia. rVIIa may represent an additional therapeutic option in such cases.
A 48-year-old woman with stage 4 marginal zone nonHodgkin's lymphoma relapsed 18 months after receiving six courses of CHOP. She was salvaged and had a stem cell collection using two courses of IVE and then underwent high-dose chemotherapy with the BEAM regimen /kg) were reinfused. The patient's HLA phenotype was A2, A24(9), and B44(12), Bw4. A week prior to PBSCT she had 100% reactivity of multispecificity. On balance, it was felt that the likely benefits of the autograft outweighed the risks and the decision was taken to proceed. On day +4 post PBSCT, she became septicaemic and showed no increment following HLA-matched platelet transfusion. On day +12 she developed severe gastrointestinal bleeding and hypotension. Simultaneously she developed a right-sided ptosis and diplopia. MRI scanning showed evidence of bleeding into the extraocular muscles of the eye. Attempts to resuscitate the patient were failing. The melaena was not controlled by HLA-matched or cross-matched platelets and intravenous tranexamic acid 1 g 8 hourly. Despite intravenous fluids and red cell transfusion she remained hypotensive. Coagulation studies showed a normal PT 11 sec (NR 10.5-13), APTT 25 sec (NR 24-36) and an elevated fibrinogen 8.4 g/l (NR 1.7-4.9). Her platelet count remained o5 Â 10 9 /l. Faced with this life-threatening situation that had failed to respond to standard therapies, a trial of recombinant factor VIIa was embarked upon. rVIIa was given at a dose of 120 mg/kg i.v. 2 hourly (total eight doses). There was a dramatic clinical response with complete subsidence of the melaena, and development of haemodynamic and neurological stability within 24 h. Transfusion was required to elevate her haemoglobin, but no further red cell support was required beyond 48 h of starting rVIIa. The cessation of bleeding did not coincide with engraftment that was documented thus; platelets ( Â 10 9 /l) 420, day 24, 450, day 27, 4100, day 31, neutrophils ( Â 10 9 /l) 40.5, day 20, 41.0, day 23. She remains in ongoing second CR 2 years post PBSCT.
A series of assays to assess the response to rVIIa were performed on samples taken from the patient, separated and stored at À701C within 2 h. The samples were thawed only once -at the time of analysis. VII:Ag (Asserchrom VII:Ag, Diagnostica Stago) ELISA, VIIa (Staclot VIIarTF) quantitative coagulation-based assay of activated factor VII in plasma, VII:c by a standard one-stage PTbased functional assay using an Electra 1800 analyser, F1+2 (Enzygnost, Dade Behring) and TAT (Enzygnost, Dade Behring) for detection of thrombin-antithrombin complexes were carried out. All assays were performed according to the manufacturer's specification. All laboratory values for controls supplied by the manufacturer fell within the expected ranges.
Laboratory analysis of the mechanisms involved in the response to rVIIa showed that the expected rise in VIIc, VIIR:Ag and VIIa-rTF were accompanied by evidence of marked thrombin generation indicated by TAT complexes and F1+2 (see Table 1 ). Monitoring of factor VII levels is not routinely indicated where this therapy is used.
The decision to proceed with a stem cell transplantation procedure involves assessment of the balance of risks and benefits to the patient. Knowledge of additional methods of supporting patients through a high-risk procedure may ease the decision-making process, allowing higher risk patients to benefit from high-dose chemotherapy procedures.
Platelet refractoriness still represents a significant, sometimes limiting, clinical problem in patients undergoing high-dose chemotherapy. Improved platelet serology helps identify significant antibodies and therefore allows provision of the optimal platelet prescription. There are, however, few other therapeutic interventions that reliably help to secure haemostasis in refractory cases.
rVIIa was initially shown to be efficacious in patients with haemophilia A and inhibitors. It has since been used Table 1 VII c=coagulant factor VII; VII Ag=factor VII antigen; VIIa-rTF=activated factor VII/tissue factor complex; TAT=throm-bin-antithrombin complex; F1+2=prothrombin fragments 1 and 2 to secure haemostasis in thrombocytopathies and other lifethreatening situations. 1,2 Successful use of rVIIa has been described after bone marrow transplantation (BMT) in three patients with generalised bleeding. However, in contrast to our case, these patients were not refractory to platelet transfusion and platelet counts were maintained at greater than 50 Â 10 9 /l. 3 A single case of successful use of VIIa for platelet refractoriness in myelodysplasia has been described. 4 The optimal dose of rVIIa in the context of thrombocytopenia is not known. However, data from clinical studies and from models of thrombocytopenia suggest that a high dose is required to produce a satisfactory thrombin burst, hence our choice of dose. The exact mechanism of action is not known, but it is likely that rVIIa results in the localised generation of thrombin on the platelet surface resulting in platelet activation, fibrin stabilisation and activation of local fibrinolysis via thrombin activated fibrinolysis inhibitor (TAFI).
In models of thrombocytopenia, it has previously been shown that thrombin generation is dependent on platelet count, and that in severe thrombocytopenia rVIIa does not normalise peak thrombin generation although it does shorten the lag phase of initiation of thrombin generation and the time to platelet activation. 5 Our clinical observation and laboratory data suggest that the establishment of haemostasis in this case of severe thrombocytopenia was associated with significant thrombin generation following rVIIa infusion. The degree of thrombocytopenia in this case led us to speculate on the site of thrombin generation. It is possible that some thrombin is being generated on the surface of mononuclear cells and in addition we wonder if the transfused platelets, although incapable of producing an increment in count may provide a suitable surface for thrombin generation. Recombinant VIIa is relatively expensive (d2733 for 4.8 mg); however, following this case we suggest that rVIIa be considered as a mode of additional therapy for life-threatening bleeding in the face of severe thrombocytopenia and platelet refractoriness, where HLAmatched platelet transfusions and other haemostatic agents have failed.
